Exercise and Genotype in Sub-acute Stroke

Sponsor
McGill University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05076747
Collaborator
(none)
50
Enrollment
1
Location
2
Arms
51.4
Anticipated Duration (Months)
1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will investigate the impact of cardiovascular exercise on brain plasticity among patients in sub-acute stages after stroke, and whether genotype modulates the response to this intervention. Participants in the experimental group will perform cardiovascular training for 8 weeks, three times/week in addition to standard therapy, while participants in the control group will perform standard therapy only. Assessments will be performed at baseline, four weeks, and 8 weeks after training.

Condition or DiseaseIntervention/TreatmentPhase
  • Behavioral: Cardiovascular training
  • Behavioral: Standard Therapy
N/A

Detailed Description

Background: Research has shown that the adult human brain has an enormous plastic capacity to adapt after injury. In people who have recently experienced a stroke, interventions that promote brain plasticity in early stages after stroke can improve long-term recovery. Cardiovascular exercise is a simple strategy to increase brain plasticity and promote neural reorganization. However, there is no information about the effects of cardiovascular exercise on brain plasticity in early phases of stroke, despite the importance of this initial period for long-term recovery. Similarly, it is not known if, depending on their genetic profile, some people will be more responsive than others to this type of exercise.

Objectives: To establish whether: 1) cardiovascular exercise improves brain plasticity during the initial phases of post-stroke recovery; 2) carrying a specific form of the BDNF gene modulates the response to cardiovascular exercise.

Design: 50 participants will perform either a progressive high-intensity cardiovascular exercise program or low-intensity stretching and toning exercise program. Both groups will undergo 8 weeks of training performed 3 times per week. Assessments will be performed at the beginning, mid-point (4 weeks) and at the end of the training period (8 weeks).

Methodology: Assessments: 1) brain plasticity by measuring changes in brain excitability, a marker of brain plasticity, with non-invasive brain stimulation; 2) BDNF levels by measuring the blood concentration of this protein; 3) Genotype by identifying the subtype of BDNF gene carried by each participant; 4) Cardiorespiratory fitness by assessing the performance during a graded exercise test.

Statistical analysis: Differences between exercise and control groups on the primary endpoint of all outcomes will be analyzed with linear mixed models. Besides baseline scores, sex, age, and type of stroke (cortical or subcortical) will be included as covariates because they can affect brain plasticity and BDNF response. T1 scores will also be included to increase the efficiency of the model. The influence of genotype on changes in primary and secondary outcomes in the exercise group will be inspected with the Freedman-Schatzkin test, a powerful technique to identify mediators of change that can be used in small-scale exercise studies.

Expected outcomes: Cardiovascular exercise will promote positive changes in brain excitability and will increase blood BDNF levels in individuals in the early phases of stroke recovery. However, the individual response to this type of exercise in relation to brain plasticity and BDNF levels will be influenced by the genotype of each participant.

Relevance: It is important to establish whether cardiovascular exercise enhances brain reorganization early after stroke post-stroke and whether genetic factors may influence the response to this intervention. This will provide clinicians with useful information which will be essential to design more individualized exercise-based treatments to optimize functional recovery in individuals with stroke.

Impact: The first weeks after a stroke are critical for functional recovery. After this initial period, the rate of recovery slows down and functional improvements become much more difficult to achieve. In Canada, health-care costs in the 6 months after stroke amount to $2.8 billion/year. Finding cost-effective rehabilitation strategies to promote recovery during the early phases post-stroke is essential to help patients return to an independent living.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Promoting Brain Plasticity During Sub-acute Stroke: The Interactive Role of Exercise and Genotype
Actual Study Start Date :
Jun 20, 2018
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Cardiovascular training

Cardiovascular training will comprise 4 weeks of moderate-to-vigorous continuous training followed by 4 weeks of progressive high-intensity interval training (HIIT) performed on recumbent steppers. This intervention will be performed in addition to the conventional standard therapy sessions. We will start with very moderate intensities and prepare participants for higher intensities. Introducing HIIT will allow us to use higher intensities over short bursts of exercise interspersed with periods of active rest. HIIT is more effective than continuous training to increase BDNF and we have shown that even a single bout of HIIT reduces interhemispheric imbalances in excitability and improves motor learning in chronic stroke.

Behavioral: Cardiovascular training
8 weeks of cardiovascular training
Other Names:
  • CT
  • Active Comparator: Standard Therapy

    Will comprise 8 weeks of the control protocol that includes regular sessions of physiotherapy, occupational therapy, and speech therapy.

    Behavioral: Standard Therapy
    8 weeks of Standard Therapy
    Other Names:
  • ST
  • Outcome Measures

    Primary Outcome Measures

    1. Cortico-spinal excitability [8 weeks]

      Single pulse motor-evoked potentials of transcranial magnetic stimulation protocol.

    2. Intra-cortical inhibition [8 weeks]

      Paired-pulse motor-evoked potentials of transcranial magnetic stimulation protocol.

    3. Intra-cortical facilitation [8 weeks]

      Paired-pulse motor-evoked potentials of transcranial magnetic stimulation protocol.

    Secondary Outcome Measures

    1. Brain-derived neurotrophic factor [8 weeks]

      5 ml of blood will be placed into lab tubes and centrifuged. Blood plasma will be pipetted into lab wells and stored in a -80 ̊C freezer for analysis with an ELISA kit sensitive to protein and mature BDNF.

    2. Cardiorespiratory fitness [8 weeks]

      We will determine the maximum oxygen consumption (VO2peak) achieved during the graded exercise test as we have shown in previous studies.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Individuals 40-80 years old

    • Who had a first-ever ischemic (cortical or subcortical) stroke confirmed by MRI/CT

    • Who had stroke 2 to 6 weeks prior to participation

    • With recordable motor-evoked potentials (MEPs) elicited with transcranial magnetic stimulation (TMS) from the affected hemisphere

    • With no serious musculoskeletal or neurological conditions other than stroke

    • With sufficient cognitive/communicative capacity to safely perform the protocols.

    Exclusion Criteria:
    • Hemorrhagic stroke

    • Cognitive impairment/dysphasia affecting informed consent

    • Concurrently enrolled in another exercise program

    • Major psychiatric or previous neurological disease

    • Absolute contraindications to TMS or exercise

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Jewish Rehabiliation HospitalLavalQuebecCanadaH7V 1R2

    Sponsors and Collaborators

    • McGill University

    Investigators

    • Principal Investigator: Marc Roig, PhD, McGill University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Marc Roig, Associate Professor, McGill University
    ClinicalTrials.gov Identifier:
    NCT05076747
    Other Study ID Numbers:
    • 199269
    First Posted:
    Oct 13, 2021
    Last Update Posted:
    Apr 6, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Marc Roig, Associate Professor, McGill University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2022